A detailed history of Ubs Oconnor LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 50,000 shares of SNDX stock, worth $681,500. This represents 0.07% of its overall portfolio holdings.

Number of Shares
50,000
Holding current value
$681,500
% of portfolio
0.07%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.93 - $24.81 $376,045 - $520,340
-20,973 Reduced 18.99%
89,481 $1.72 Million
Q2 2024

Aug 14, 2024

BUY
$18.82 - $23.79 $38,072 - $48,127
2,023 Added 1.87%
110,454 $2.27 Million
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $246,020 - $306,682
12,482 Added 13.01%
108,431 $2.58 Million
Q4 2023

Feb 14, 2024

BUY
$11.39 - $21.67 $1.09 Million - $2.08 Million
95,949 New
95,949 $2.07 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $771M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.